The BIS ETF is a passive inverse product that seeks amplified returns in the opposite direction of the daily performance of the Nasdaq Biotechnology Index. It is structured for short-term responses to index declines or partial hedging of existing biotech exposure, and serves a different purpose than typical long-term sector ETFs.

It is suited for investors who want to manage short-term downside risk in the biotech sector and who understand the daily reset structure and the potential for losses, allowing them to monitor the position on an ongoing basis.

The ETF is operated by ProShares using a passive (index-tracking) management approach.

The BIS ETF uses derivatives to achieve amplified inverse exposure to the day-to-day moves of the Nasdaq Biotechnology Index. As a result, even when the index moves in the same direction over several days, cumulative performance can differ from a simple inverse calculation, and path dependency increases during periods of high volatility.

• Daily inverse exposure focused on the biotech sector
• Traded on an exchange rather than through individual short selling
• Designed for short-term risk management given its daily reset

Assets under management (AUM) stand at $1.8M, with a total expense ratio of 0.95% annually.

This product does not simply mirror the long-term direction of the index in reverse. Instead, it realigns its target exposure every day. Therefore, the timing of trades, the holding period, and the intraday volatility of the biotech sector should all be examined together, and the gap in cumulative performance can widen over longer holding periods.

The BIS ETF's performance can improve relatively during downturn phases in the biotech sector, but it can be disadvantaged when the sector rebounds or exhibits a high-volatility sideways pattern. Clinical results, regulatory decisions, funding conditions, and shifts in M&A expectations can all drive sharp short-term moves.

The biotech sector combines the price behavior of early-stage developers and large pharmaceutical companies, making it highly sensitive to risk appetite and policy variables. In this environment, demand for inverse ETFs can vary based on hedging needs or changes in short-term outlooks, and market liquidity and trading costs should also be reviewed before trading.

Its role as a tool for responding to biotech-sector declines is a strength, but the daily reset and high volatility limit its suitability for long-term holding.

The SQQQ ETF in the table is an inverse product designed for declines in the broad technology-stock index, while the SOXS ETF is more concentrated on downside moves in the chip-making sector. The SH ETF is closer to a defensive tool for the broad large-cap market, and the PSQ ETF can be used to inversely track the flow of large-cap Nasdaq growth stocks. The SPXU ETF pursues amplified downside exposure to the large-cap market, so it differs from the BIS ETF in its underlying sector and daily volatility characteristics.

When reviewing the BIS ETF, investors should examine not only their short-term view on the biotech sector but also the daily reset structure and intended holding period. This product is closer to a tactical tool for managing a specific risk than a long-term core holding, so it is important to set entry reasons and exit criteria in advance.

The biotech sector is sensitive to clinical development, regulatory decisions, funding conditions, and M&A expectations, so large directional shifts can occur even over short periods. The BIS ETF provides amplified exposure in the opposite direction of this volatility, meaning investors must accept losses during rebounds and the cumulative performance gap caused by the daily reset.

The BIS ETF is an inverse ETF worth considering for investors seeking a tactical approach to biotech-sector downside risk. However, because it differs in nature from a long-term sector investment, it is important to keep the holding period short and consistently monitor the difference between the daily target and actual cumulative performance.